Marie Thibault
Stock Analyst at BTIG
(3.91)
# 518
Out of 4,784 analysts
72
Total ratings
52.94%
Success rate
9.34%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $12 | $4.40 | +172.73% | 1 | Mar 20, 2025 | |
| EMBC Embecta | Upgrades: Buy | $26 | $12.28 | +111.73% | 2 | Nov 27, 2024 | |
| PODD Insulet | Maintains: Buy | $260 → $270 | $258.75 | +4.35% | 4 | Nov 8, 2024 | |
| MASI Masimo | Maintains: Buy | $166 → $170 | $163.55 | +3.94% | 3 | Oct 14, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $40.43 | +60.77% | 8 | Oct 14, 2024 | |
| BSX Boston Scientific | Maintains: Buy | $84 → $93 | $99.36 | -6.40% | 7 | Oct 14, 2024 | |
| HAE Haemonetics | Initiates: Buy | $112 | $63.19 | +77.24% | 1 | Sep 10, 2024 | |
| ATRC AtriCure | Maintains: Buy | $58 → $53 | $31.83 | +66.51% | 4 | Jul 31, 2024 | |
| DXCM DexCom | Maintains: Buy | $156 → $120 | $67.74 | +77.15% | 7 | Jul 26, 2024 | |
| XAIR Beyond Air | Downgrades: Neutral | n/a | $0.27 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.75 | - | 3 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $20 | $13.15 | +52.09% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $105.00 | +33.33% | 7 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $2.14 | +40.19% | 3 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $125 | $130.82 | -4.45% | 11 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $1.82 | +284.62% | 1 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.77 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.68 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $152.41 | -96.06% | 1 | Apr 9, 2020 |
Orchestra BioMed Holdings
Mar 20, 2025
Initiates: Buy
Price Target: $12
Current: $4.40
Upside: +172.73%
Embecta
Nov 27, 2024
Upgrades: Buy
Price Target: $26
Current: $12.28
Upside: +111.73%
Insulet
Nov 8, 2024
Maintains: Buy
Price Target: $260 → $270
Current: $258.75
Upside: +4.35%
Masimo
Oct 14, 2024
Maintains: Buy
Price Target: $166 → $170
Current: $163.55
Upside: +3.94%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $40.43
Upside: +60.77%
Boston Scientific
Oct 14, 2024
Maintains: Buy
Price Target: $84 → $93
Current: $99.36
Upside: -6.40%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $63.19
Upside: +77.24%
AtriCure
Jul 31, 2024
Maintains: Buy
Price Target: $58 → $53
Current: $31.83
Upside: +66.51%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $67.74
Upside: +77.15%
Beyond Air
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.27
Upside: -
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.75
Upside: -
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $13.15
Upside: +52.09%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $105.00
Upside: +33.33%
Mar 29, 2023
Maintains: Buy
Price Target: $4 → $3
Current: $2.14
Upside: +40.19%
Jan 26, 2023
Maintains: Buy
Price Target: $120 → $125
Current: $130.82
Upside: -4.45%
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $1.82
Upside: +284.62%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.77
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.68
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $152.41
Upside: -96.06%